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Serum neutrophil gelatinase-associated lipocalin as a biomarker of disease 
activity in pediatric lupus nephritis  
 
INTRODUCTION 
Renal involvement is one of the main determinants 
of poor prognosis of systemic lupus erythematosus 
(SLE) and is more frequently encountered in 
children than in adults with SLE1. Currently 
available renal biomarkers, i.e. measures of the 
degree of SLE renal disease activity and severity, 
are too insensitive to allow for early identification 
of patients with active SLE nephritis, prohibiting 
timely initiation of therapy to avoid permanent 
renal damage2. Randomized clinical trials in SLE 
are hindered by the lack of high-quality biomarkers 
to verify the effects of therapies within a short 
period of time3.  
Neutrophil gelatinase-associated lipocalin 
(NGAL) is a member of the lipocalin family of 
proteins that has been extensively studied in acute 
kidney injury4. NGAL is one of the most robustly 
expressed proteins in the kidney following ischemic 
or nephrotoxic injury in both animals5 and humans6. 
Importantly, a prospective pediatric study 
demonstrated that concentrations of NGAL in urine 
and plasma represent novel, sensitive, and specific 
biomarkers for early identification of acute kidney 
injury following cardiac surgery7. 
Given the role NGAL plays in kidney injury, 
we were stimulated to investigate its serum levels in 
a group of children and adolescents with SLE in 
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SLE1 prior to the age of 16 years. Their ages ranged 
from 5 to 21 years with a mean age ± (SD): 16.48 
±3.524 [median=14.5 years]. They were recruited 
on one of their routine visits to the Pediatric Allergy 
and Immunology Clinic, Children's Hospital, Ain 
Shams University.  
A sample of 20 age and sex matched healthy 
children were studied as controls. Their ages ranged 
from 9 to 19 years with a mean age ± (SD): 14.8 
±3.381 [median=15.5 years]. They were obtained 
from the out patient clinic of the same hospital. 
 
Methods 
The medical records were reviewed to screen for 
pre- existing renal disease in patients and to obtain 
pediatric SLE-specific information. Review of 
system information and the results of routine 
laboratory testing at the time of the study visits 
were recorded. Relevant demographic data of all 
participants were obtained.  
All patients and controls were subjected to the 
following: 
1. Clinical history taking and  examination 
stressing  on disease activity in SLE patients 
measured by SLE disease activity index 
(SLEDAI)8, and data about lupus nephritis: 
- Presence or absence. 
- Clinical presentations. 
- Laboratory evidence. 
2. Laboratory testing (for patients only): 
a. Serum creatinine and BUN using synchron 
CX7 autoanalyzer.  
b. Urinalysis, urinary protein to creatinine ratio, 
24 hours protein in urine using synchron CX7 
autoanalyzer. 
c. CBC on coulter counter. 
d. ESR by Westergen method. 
e.  Anti-double stranded DNA antibodies were 
assessed employing indirect immuno-
fluorescent test (IMMCO Diagnostics, USA). 
f. Complement 3 (C3) assay using turbidimetery 
(Turbiquant C3, Behringwerke Diagnostics- 
Marburg, Germany). 
 
Quantitative measurement of serum NGAL 
This was done by enzyme-linked immunosorbent 
assay (ELISA) using (Human Lipocalin-2/NGAL 
ELISA, Biovendor, Czech Republic, that specifically 
detects human NGAL). 
Test Principle 
In the BioVendor Human Lipocalin-2/NGAL 
ELISA, the Standards, Quality controls and samples 
were incubated in microtiter wells pre-coated with 
polyclonal anti-human lipocalin-2 antibody. After 
incubation and a washing, biotin-labeled polyclonal 
anti-human lipocalin-2 antibody was added and 
incubated with captured lipocalin-2. After another 
washing, the streptavidin-HRP conjugate was 
added. After incubation and the last washing step, 
the remaining conjugate was allowed to react with 
the substrate solution (TMB). The reaction was 
stopped by addition of acidic solution, and 
absorbance of the resulting yellow product was 
measured spectrophotometrically at 450nm. The 
absorbance was proportional to the concentration of 
lipocalin-2. A standard curves was constructed by 
plotting absorbance values against concentrations of 
standards, and the concentrations of unknown 
samples were determined using this standard curve. 
 
Statistical analysis 
Analysis of the data was done on IBM computer 
system using SPSS version 15 (Statistical program 
for social science group USA). Data were presented 
as mean±SD for parametric data in addition to 
median and interquartile range (IQR) (the 
difference between 75th and 25th percentiles) for non 
parametric data. 
Comparison between groups was done using 
Mann Whitney test for non parametric variables. 
Spearman correlation co-efficient rank test was 
used to rank different variables against each other in 
linear correlation. For all tests (probability) P 
values < 0.05 was considered significant. 
 
RESULTS 
In the studied group, 22 patients had nephritis (2 
males and 20 females) with a frequency of 73% and 
8 patients had SLE without nephritis (1 male and 7 
females). 
Serum NGAL was significantly higher in SLE 
patients [mean±SD: 271±126.480; median: 255 
ng/ml] in comparison to the controls [mean 
±SD:62.40 ±24.442; median: 75 ng/ml], (z= -5.962, 
p<0.001). It was significantly higher in SLE 
patients with nephritis [M±SD: 295.91±125.941; 
median: 277.50 ng/ml], and  in patients without 
nephritis [mean ±SD: 202.50±106.670; median: 
172.50 ng/ml]  in comparison to the controls (z= -
5.568, p<0.001 and z= -4.121, p<0.001) 
respectively. 
Serum NGAL was higher in SLE patients with 
nephritis in comparison to those without nephritis, 
with borderline statistical significance (z= -1.958, 
p= 0.05) ( Fig 1). 
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There was a significant correlation between serum 
NGAL and SLEDAI in SLE patients as a group, (r= 
0.485, p<0.01) while there was no correlation 
between serum NGAL and age and disease duration 
(Fig 2). 
There was a significant correlation between 
serum NGAL and age and SLEDAI of SLE patients 
without nephritis (r= -0.839, p<0.01 and r=0.803, 
p<0.05 respectively), while there was no correlation 

















r =0.485                          p = 0.007 
Figure 2. Correlation between serum NGAL and 
SLEDAI in SLE patients. 
 
 
There was a significant correlation between 
serum NGAL and prot/creat in urine, 24hr urinary 
protein and BUN (r= 0.367, p< 0.05; r=0.466, p< 
0.01 and r= 0.470, p< 0.01 respectively), while 
there was no significant correlation between serum 
NGAL and the other laboratory data of SLE 
patients (Figs 3 and 4). 
There was a significant correlation between 
serum NGAL and disease duration in SLE patients 
with nephritis (r= 0.481, p<0.05) , while there was 
no correlation between serum NGAL and age and 


















































r =   0.466                                p = 0.009 r = 0.486                    p = 0.009 
Figure 3. Correlation between serum NGAL and 
BUN in SLE patients. 
Figure 4. Correlation between serum NGAL and 
24hrs urinary protein in SLE patients. 
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DISCUSSION 
Renal involvement is one of the main determinants 
of poor prognosis of SLE and more frequently 
encountered in children than in adults with SLE1. In 
the present cross sectional study on pediatric SLE 
patients we sought to investigate the relation of 
serum NGAL to disease activity with special 
emphasis on renal involvement. 
The results showed that serum NGAL was 
significantly higher in SLE patients in comparison 
to the controls as it is one of the substances 
expressed in immature neutrophil precursors and in 
epithelial cells during both inflammation and 
neoplastic transformation. When we compared 
serum NGAL in the two groups of pediatric SLE 
patients (patients with nephritis and those without 
nephritis) we found that serum NGAL was higher 
in SLE patients with nephritis in comparison to 
those without nephritis with borderline significance. 
In 2005, Mishra and his colleagues7 measured 
plasma and urinary NGAL in children who 
developed acute kidney injury after cardiac surgery 
necessitating extra-corporeal cardio-pulmonary 
bypass. A significant rise in the average plasma 
NGAL levels was seen as early as 2 hours post-
operatively, urinary NGAL levels showed similar 
results although sensitivity and specificity of the 
test were somewhat higher than for plasma NGAL 
in their study, which means that NGAL can be 
considered as an early biomarker for acute kidney 
injury. 
In a previous study by Suzuki and his 
colleagues9, plasma concentration of NGAL 
fluctuated widely in pediatric SLE patients, and 
there was no significant increase with renal disease 
activity change while there was marked increase in 
urinary NGAL with worsening renal disease 
activity in pediatric patients with lupus nephritis. 
Another study showed that urinary NGAL was 
significantly higher in adult lupus patients with 
active nephritis than in those without nephritis10. 
Serum NGAL as a marker of renal injury has 
also been studied in patients subjected to 
percutaneous coronary interventions (PCI) with 
coronary angiography 11. In this study  the chief risk 
for the kidneys is thought to be the radiographic 
contrast agents used in this procedure. A significant 
(but modest) rise in serum NGAL was seen in the 
first sample taken at two hours after PCI; this 
peaked at four hours, while the rise in urine NGAL 
peaked at eight hours. Multivariate analysis was 
performed with serum creatinine, which did not rise 
significantly during the 48 hours of the study, as 
well as with serum cystatin C, which peaked at 24 
hours. None of the patients developed acute renal 
dysfunction. This is an interesting study of potential 
subclinical renal injury from the contrast agent, in 
which NGAL was clearly the earliest responding 
marker. Another study  showed that serum NGAL 
was significantly increased in critically ill children 
with acute kidney injury compared with those 
without acute kidney injury12.   
In our study, we found that there was a 
significant correlation between serum NGAL and 
SLEDAI in all investigated patients, this means that 
disease activity in SLE patients affects serum 
NGAL level. Our results were in agreement with 
other studies in pediatric SLE, the most recent was 
that of Suzuki and his colleagues9 where they found 
that children with SLE had higher plasma NGAL 
during activity.  
As regard disease duration we found that there 
was a significant correlation between serum NGAL 
and disease duration in SLE patients with nephritis, 
this means that serum NGAL may have a role in 
chronic kidney disease, this is supported by a 
previous study of Mitsnefes and his colleagues13 
which showed that children with chronic kidney 
disease in stages 2-4 had serum NGAL levels that 
correlated significantly, if not highly so, with 
glomerular filtration rate (GFR), and at lower 
values of GFR, serum NGAL level correlated rather 
better than cystatin C level.  
The present study revealed a significant 
positive correlation between serum NGAL and 
protein/creatinine ratio, 24 hr urinary protein and 
BUN. The correlation of serum NGAL and 
proteinuria, which is an important parameter for 
disease activity in lupus nephritis,  was supported 
by a previous study that suggested that  NGAL 
might be expressed by the damaged tubule to 
induce re-epithelialisation14, Further support for this 
notion derives from the identification of NGAL as a 
regulator of epithelial morphogenesis in cultured 
kidney tubule cells15, and as an iron-transporting 
protein that is complementary to transferrin during 
nephrogenesis16.  
The current study did not find significant 
correlation between serum NGAL and other 
laboratory parameters including (Hb, WBCs, 
platelets, ESR, creatinine clearance, serum 
creatinine , antiDNA and C3).  
In a previous study in adult SLE by Pitashny 
and his colleagues10  there was no correlation 
between urinary NGAL and Hb, WBCs, platelets. 
They could not find any correlation between the 
levels of urinary NGAL and the levels of 
complement or anti-dsDNA antibodies in adult 
patients. Although these are commonly used 
indicators of renal disease activity in clinical 
Serum NGAL in pediatric lupus nephritis 
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practice17, the association between these parameters 
and disease risk is imperfect18. The absence of a 
correlation between NGAL and anti-dsDNA 
antibodies is, however, somewhat surprising in light 
of in vitro studies in which pathogenic anti-dsDNA 
antibodies up-regulated the expression of NGAL in 
mesangial cells19. 
One possible explanation may be the relative 
lack of sensitivity of the anti-dsDNA assays for 
specific detection of nephritogenic anti-dsDNA 
antibodies that induce renal disease and up-regulate 
lipocalin-2 expression in the kidneys. Similarly, 
although the role of complement in LN 
pathogenesis has been well described20, in the 
present study increased NGAL was not associated 
with complement consumption. 
Previous studies have indicated that other forms 
of renal injury, including ischemia, nephrotoxic 
drugs, or infection, can also up-regulate lipocalin-2 
expression in the kidneys21. Therefore, elevations in 
serum NGAL are not specific to nephritis in SLE. 
Nevertheless, this does not detract from a 
potentially valuable role for NGAL in lupus 
patients as suggested by the results of our study, in 
the initial diagnosis of kidney involvement, or in 
subsequent monitoring of disease activity. 
Our results suggest that serum NGAL 
represents a novel biomarker for disease activity in 
pediatric SLE  patients as evident from its 
correlation with SLEDAI, and a marker for severity 
of renal involvement as obvious from its correlation 
with protein excretion and BUN. 
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